Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TBC Bank impresses with record fourth quarter

(Sharecast News) - TBC Bank impressed on Wednesday by reporting record revenues and a big jump in profits in the fourth quarter, with the UK-listed Georgian bank confident of hitting its strategic targets for 2025. Total operating income was up 22.6% year-on-year at an all-time high of 784m Georgian lari (£226m) in the final three months of 2024, with net interest income rising 14.9% to GEL508m, net fee and commission income up 34.4% at GEL148m, and other non-interest income was 46.4% higher at GEL128m.

Results were driven by the payments business in Georgia and strong growth in Uzbekistan, where TBC scaled up during the year with total users rising 37% to 18m and its loan book more than doubling.

Adjusted net profits for the fourth quarter were up 18.2% at GEL344m.

For 2024 as a whole, total operating income was 19.4% higher at GEL2.83bn, while adjusted net profit rose 15.6% to a record GEL1.32bn.

TBC declared a final dividend of GEL5.55, taking the full-year payout to GEL8.10, up 12% on 2023.

"As a team, we achieved a great deal in 2024, but as always there remains much to do, and we look forward to 2025 being another year of further scaling up our business in Uzbekistan and continuing to deliver strong and profitable growth in Georgia. I am confident we are fully on track to meet the mid-term targets we have set for 2025," said chief executive Vakhtang Butskhrikidze.

Shares were up 6.2% at 3,925.02p by 0854 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.